Pneumocystis Jirovecii Genotyping

Launched by NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST · May 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a fungus called Pneumocystis jirovecii (PCP), which can cause serious lung infections in people with weakened immune systems, such as cancer patients. The researchers want to understand how this fungus spreads in hospitals when multiple patients become infected. They will use a special laboratory test to analyze samples from patients who have tested positive for PCP. By looking at the genetic information of the fungus, they can determine if infections in different patients are related, which helps healthcare providers identify outbreaks and prevent further spread.

To participate in this trial, individuals must be adults over 18 years old and have a positive PCP diagnosis confirmed by specific laboratory tests. Those who have a negative diagnosis, are under 18, or have lower amounts of the fungus in their samples will not be included. Participants will provide samples that will be analyzed to help improve the understanding of how PCP is transmitted in healthcare settings. This research aims to enhance patient safety and reduce the risks of infections in vulnerable populations.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Total nucleic acid extracts from adult patients (over 18 years old) with a positive PCP diagnosis (\& detected at \> 50 copies/10ul) from routine respiratory panel testing.
• Exclusion Criteria:
• • Total nucleic acid extracts from patients with a negative PCP diagnosis from routine respiratory panel testing
• • Total nucleic acid extracts from non-adult patients (under 18 years old).
• • PCP positive total nucleic extract samples with \< 50 copies/10ul.
• • Patients included on the UK National Opt-Out register